PE20090931A1 - Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa - Google Patents

Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Info

Publication number
PE20090931A1
PE20090931A1 PE2008001841A PE2008001841A PE20090931A1 PE 20090931 A1 PE20090931 A1 PE 20090931A1 PE 2008001841 A PE2008001841 A PE 2008001841A PE 2008001841 A PE2008001841 A PE 2008001841A PE 20090931 A1 PE20090931 A1 PE 20090931A1
Authority
PE
Peru
Prior art keywords
liasa
pharmaceutical composition
composition containing
steroid inhibitor
thiofen
Prior art date
Application number
PE2008001841A
Other languages
English (en)
Inventor
Masuo Yamaoka
Takahito Hara
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090931(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20090931A1 publication Critical patent/PE20090931A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN INHIBIDOR DE ESTEROIDE C17,20 LIASA DE FORMULA (I) DONDE n ES DE 1 A 3; Ar ES UN COMPUESTO DE FORMULA (1), (2), ENTRE OTROS, DONDE m1 ES DE 1 A 4; m2 ES DE 0 A 3; R1 Y R2 SON CADA UNO H, HIDROXILO, TIOL, AMINO, ENTRE OTROS; m3 ES DE 1 A 5; m4 ES DE 0 A 4; R3 Y R4 SON CADA UNO H, HIDROXILO, ACILO, AMINO, ENTRE OTROS; SIENDO COMPUESTOS PREFERIDOS: (+/-)-7-(5-METOXIBENZO[b]TIOFEN-2-IL)-6,7-DIHIDRO-5H-PIRROLO[1,2-c]IMIDAZOL-7-OL, (+/-)-7-(5-FLUOROBENZO[b]TIOFEN-2-IL)-6,7-DIHIDRO-5H-PIRROLO[1,2-c]IMIDAZOL-7-OL, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE CANCER DE PROSTATA INDEPENDIENTE DE ANDROGENOS
PE2008001841A 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa PE20090931A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007280813 2007-10-29

Publications (1)

Publication Number Publication Date
PE20090931A1 true PE20090931A1 (es) 2009-08-03

Family

ID=40591618

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013000161A PE20130603A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa
PE2008001841A PE20090931A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2013000161A PE20130603A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Country Status (17)

Country Link
US (2) US20100261689A1 (es)
EP (1) EP2205239A2 (es)
JP (1) JP5430576B2 (es)
KR (1) KR20100088144A (es)
CN (1) CN101909622B (es)
AR (1) AR069079A1 (es)
AU (1) AU2008319767B8 (es)
CA (1) CA2703780A1 (es)
CL (1) CL2008003198A1 (es)
IL (1) IL205368A (es)
MX (1) MX2010004405A (es)
NZ (1) NZ585473A (es)
PE (2) PE20130603A1 (es)
RU (1) RU2481107C2 (es)
SG (1) SG185930A1 (es)
TW (1) TWI426901B (es)
WO (1) WO2009057795A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083916A1 (es) * 2010-11-18 2013-04-10 Takeda Pharmaceutical Metodo para tratar el cancer de mama y cancer de ovarios
JP2014513730A (ja) * 2011-05-17 2014-06-05 武田薬品工業株式会社 癌を治療するための薬学的組成物および方法
US10201549B2 (en) 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0880540B1 (en) * 1996-02-14 2002-06-12 Aventis Pharmaceuticals Inc. 17-beta-cyclopropyl(amino/oxy) 4-aza steroids as active inhibitors of testosterone 5-alpha-reductase and c17-20-lyase
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
ATE327237T1 (de) * 2000-11-17 2006-06-15 Takeda Pharmaceutical Imidazol derivate, ihre herstellung und ihre verwendung
CN100588649C (zh) * 2002-01-10 2010-02-10 武田药品工业株式会社 制备稠合咪唑化合物的方法、稳定形式的里福马斯基试剂及其制备方法
US20040242618A1 (en) * 2003-04-01 2004-12-02 Lardy Henry A. Antiandrogens with marginal agonist activity and methods of use
US20060217316A1 (en) * 2003-04-02 2006-09-28 Ragab El-Rashidy Method for the treatment of prostate cancer
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US8828429B2 (en) * 2005-03-03 2014-09-09 Takeda Pharmaceutical Company Limited Release-control composition
CA2606329A1 (en) * 2005-03-09 2006-09-21 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
CA2661422C (en) * 2006-08-25 2017-06-27 Cougar Biotechnology, Inc. Methods and compositions for treating cancer
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
RU2481107C2 (ru) 2013-05-10
AU2008319767A8 (en) 2014-01-09
AU2008319767B8 (en) 2014-01-09
CL2008003198A1 (es) 2009-12-18
KR20100088144A (ko) 2010-08-06
IL205368A0 (en) 2010-12-30
TWI426901B (zh) 2014-02-21
AU2008319767A2 (en) 2010-06-17
EP2205239A2 (en) 2010-07-14
RU2010121765A (ru) 2011-12-10
AR069079A1 (es) 2009-12-30
AU2008319767A1 (en) 2009-05-07
SG185930A1 (en) 2012-12-28
US20140256693A1 (en) 2014-09-11
AU2008319767B2 (en) 2013-12-19
WO2009057795A3 (en) 2009-07-09
CA2703780A1 (en) 2009-05-07
US20100261689A1 (en) 2010-10-14
CN101909622A (zh) 2010-12-08
CN101909622B (zh) 2013-06-19
WO2009057795A8 (en) 2010-05-14
TW200927097A (en) 2009-07-01
JP5430576B2 (ja) 2014-03-05
JP2011502114A (ja) 2011-01-20
IL205368A (en) 2014-08-31
MX2010004405A (es) 2010-05-03
WO2009057795A2 (en) 2009-05-07
NZ585473A (en) 2012-03-30
PE20130603A1 (es) 2013-05-30

Similar Documents

Publication Publication Date Title
UY29530A1 (es) Compuestos quimicos
PE20090156A1 (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas
CO6190521A2 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa
PE20050081A1 (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
MX2009001829A (es) Anticuerpo especifico prlr y sus usos.
NZ580226A (en) Dimer compounds as inhibitors of iap
UY30748A1 (es) Compuesto0s novedosos
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
MX2010005095A (es) Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion.
TW200732313A (en) Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
ES2583010T3 (es) Nuevos inhibidores de la ruta de Stat3 e inhibidores de células madre del cáncer
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
TW200716584A (en) Dihydrobenzofuran derivatives and uses thereof
EA201100037A1 (ru) Органические соединения
EA200970605A1 (ru) Ингибиторы mapk/erk-киназ
UY29169A1 (es) Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica
MX2007013624A (es) Inhibidores de proteina cinasa.
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
AR063869A1 (es) Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
GT201000172A (es) Inhibidores de cinesina como productos terapéuticos para el cáncer
EA201190236A1 (ru) Новые производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью
MX2009001341A (es) Anticuerpos especificos de ephb3 y usos de los mismos.

Legal Events

Date Code Title Description
FC Refusal